Advertisement
Advertisement
BCYC
Bicycle Therapeutics plc - ADR
4.74
USDSponsored
+0.02
+0.42%
May 13, 15:59 UTC -4
Closed
Pre-Market
4.83
+0.09
+1.88%
BCYC Earnings Reports
Positive Surprise Ratio
BCYC beat 13 of 28 last estimates.
46%
Next Report
Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$5.65M
/-$0.59
Implied change from Q1 26 (Revenue/ EPS)
+536.68%
/-32.18%
Implied change from Q2 25 (Revenue/ EPS)
+93.40%
/-47.79%
Bicycle Therapeutics plc - ADR earnings per share and revenue
On Apr 30, 2026, BCYC reported earnings of -0.87 USD per share (EPS) for Q1 26, missing the estimate of -0.63 USD, resulting in a -37.38% surprise. Revenue reached 887.00 thousand, compared to an expected 7.41 million, with a -88.03% difference. The market reacted with a -0.21% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.59 USD, with revenue projected to reach 5.65 million USD, implying an decrease of -32.18% EPS, and increase of 536.68% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Bicycle Therapeutics plc - ADR's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Bicycle Therapeutics plc - ADR reported EPS of -$0.87, missing estimates by -37.38%, and revenue of $887.00K, -88.03% below expectations.
How did the market react to Bicycle Therapeutics plc - ADR's Q1 2026 earnings?
The stock price moved down -0.21%, changed from $4.73 before the earnings release to $4.72 the day after.
When is Bicycle Therapeutics plc - ADR expected to report next?
The next earning report is scheduled for Aug 06, 2026.
What are the forecasts for Bicycle Therapeutics plc - ADR's next earnings report?
Based on 7
analysts, Bicycle Therapeutics plc - ADR is expected to report EPS of -$0.59 and revenue of $5.65M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement